Buloxibutid

Overview

Buloxibutid ( AT2 receptor agonist C21) is an orally active, selective angiotensin II type 2 receptor ( AT2R ) agonist, with a K i value of 0.4 nM for porcine AT2R . Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13 ) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis.

Application

Products | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > TGF-β Receptor | Products > Signaling Pathways > MMP | Products > Signaling Pathways > Angiotensin Receptor | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > TGF-beta/Smad

Product Information

• Catalog No.: HY-100113
• CAS No.: 477775-14-7
• Molecular Formula: C23H29N3O4S2
• Molecular Weight: 475.62
• Purity: 98.94%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (4.37 mM); Clear solution
• Availability: In-stock

Source

Original product source